WAVE Life Sciences (WVE) Set to Release Earnings on Tuesday

Key Points

• WAVE Life Sciences is expected to report Q3 2026 results before the market opens on October 27. Analysts forecast a loss of $0.34 per share and revenue of $4.51 million.
• The company missed estimates in its previous quarter, reporting a $0.34 per-share loss versus the expected $0.30 loss and revenue of $2.27 million versus estimates of $7.45 million. Analysts project full-year and next-year losses of $1.12 and $1.29 per share, respectively.
• WVE shares opened at $3.37, near their one-year low of $3.04 and well below the $21.73 high. Despite recent insider selling and mixed analyst actions, the stock carries a “Moderate Buy” consensus rating with a $21.53 average price target.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $4.51 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. On average, analysts expect WAVE Life Sciences to post ($1.12) EPS for the current fiscal year and ($1.29) EPS for the next fiscal year.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $3.37 on Thursday. The stock has a market capitalization of $664.67 million, a P/E ratio of -3.09 and a beta of -1.43. The company has a 50-day moving average price of $4.31 and a 200-day moving average price of $5.64. WAVE Life Sciences has a 1 year low of $3.04 and a 1 year high of $21.73.

Insiders Place Their Bets

In other news, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Heidi L. Wagner sold 7,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director owned 44,930 shares of the company's stock, valued at approximately $270,029.30. This represents a 13.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,564 shares of company stock worth $132,476 over the last ninety days. Insiders own 24.34% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on WVE. Wedbush set a $13.00 price target on shares of WAVE Life Sciences in a research report on Friday, October 2nd. Zacks Research downgraded WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. B. Riley Financial decreased their price objective on WAVE Life Sciences from $31.00 to $22.00 and set a "buy" rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a report on Wednesday, September 23rd. They set a "neutral" rating for the company. Finally, William Blair initiated coverage on WAVE Life Sciences in a research note on Friday, October 16th. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, WAVE Life Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.53.

About WAVE Life Sciences

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.